Differentiation of adrenal adenomas from nonadenomas using CT histogram analysis method: A prospective study

Objective

The objective of our study was to prospectively evaluate the effectiveness of computed tomography (CT) histogram analysis method in the differentiation of benign and malignant adrenal masses.

Materials and Methods

Between March 2007 and June 2008, 94 patients (46 males, 48 females, age range: 30-79 years, mean age: 57.7 years) with 113 adrenal masses (mean diameter: 3.03 cm, range: 1.07-8.02 cm) were prospectively evaluated. These included 66 adenomas, 45 metastases and 2 pheochromocytomas. Histogram analysis method was performed using a circular region of interest (ROI) and mean attenuation, total number of pixels, number of negative pixels and subsequent percentage of negative pixels were detected on both unenhanced and delayed contrast-enhanced CT images for each adrenal mass. A mean attenuation threshold of 10 Hounsfield unit (HU) for unenhanced CT and 5% and 10% negative pixel thresholds for both unenhanced and delayed contrast-enhanced CT were calculated by a consensus of at least two reviewers and the correlation between mean attenuation and percentage of negative pixels was determined. Final diagnoses were based on imaging follow-up of minimum 6 months, biopsy, surgery and adrenal washout study.

Results

51 of 66 adenomas (77.3%) showed attenuation values of ≤10 HU and 15 (22.7%) adenomas showed more than 10 HU on unenhanced CT. All of these adenomas contained negative pixels on unenhanced CT. Eight of 66 (12.1%) adenomas showed a mean attenuation value of ≤10 HU on delayed contrast-enhanced scans and 45 adenomas (68.2%) persisted on containing negative pixels. All metastases had an attenuation value of greater than 10 HU on unenhanced CT images. 21 of 45 (46.6%) metastases contained negative pixels on unenhanced images but only seven metastases (15.5%) had negative pixels on delayed contrast-enhanced images. Two pheochromocytomas had negative pixels on both unenhanced and delayed contrast-enhanced CT images. Increase in the percentage of negative pixels yielded high correlation with mean attenuation decreases, both on unenhanced and delayed contrast-enhanced CT. Our sensitivity was 90.9% for the 10% negative pixel percentage threshold compared to 77.2% sensitivity for ≤10 HU mean attenuation threshold for unenhanced CT. Both methods gave a 100% specificity for the diagnosis of adenoma. We also obtained a 37.9% sensitivity for 5% negative pixel threshold and a slightly lower sensitivity of 28.8% for 10% negative pixel threshold compared to the 12.1% sensitivity of ≤10 HU mean attenuation threshold while maintaining 100% specificity for contrast-enhanced CT.

Conclusion

The CT histogram analysis is a simple and easily applicable method which provides higher sensitivity than the commonly used 10 HU threshold mean attenuation method of unenhanced CT and can replace it for the diagnosis of an adenoma. But with contrast-enhanced CT, although 100% specificity is being maintained, the sensitivities obtained are very poor for each method and is therefore likely to limit CT histogram analysis to be used as a clinically useful adjunct in the diagnosis of adenoma.     

动态增强CT检查对肾上腺腺瘤与非腺瘤的鉴别诊断价值

目的探讨动态增强CT检查技术对肾上腺腺瘤与非腺瘤的鉴别诊断价值并优选出有意义的参数，以进一步明确两者的鉴别诊断标准。资料与方法对44例共49个肾上腺肿瘤先平扫再行动态增强CT检查，观察以肿瘤的CT绝对值、绝对开始廓清率及相对开始廓清率作为标准鉴别肾上腺腺瘤与非腺瘤的诊断价值。结果延时3min，以36％的绝对开始廓清率或35％的相对开始廓清率分别与CT绝对值58HU相结合作为标准，对腺瘤有较高的诊断价值，对于腺瘤中的乏脂质性腺瘤与非腺瘤的鉴别诊断也具有同样的价值。结论以肿瘤的廓清率与延时增强后的CT绝对值作为联合标准，能明显提高腺瘤的诊断价值。     

Adrenal masses: CT characterization with histogram analysis method

PURPOSE: To evaluate a histogram analysis method for differentiating adrenal adenoma from metastasis at computed tomography (CT). MATERIALS AND METHODS: In a retrospective review of 2 years of clinical CT records, 223 adrenal adenomas in 193 patients (115 with contrast material-enhanced CT, 43 with unenhanced and enhanced CT, and 35 with unenhanced CT) and 31 metastases (25 patients with enhanced CT) were found. In 158 patients with adenomas at enhanced CT, diagnosis was based on stable mass size for more than 1 year (n = 135) and characteristic signal intensity decrease at chemical shift magnetic resonance imaging (n = 23). In 35 patients with adenomas at unenhanced CT, mean attenuation was 10 HU or less. Diagnosis of all metastases was based on rapid growth of a mass or new mass in less than 6 months in patients with cancer. Adrenal metastases with extensive necrosis were excluded. Histogram analysis was performed in a circular region of interest (ROI) for mean attenuation, number of pixels, and range of pixel attenuation for all pixels and for the subset of pixels with less than 0 HU ("negative" pixels). Correlation between mean attenuation and percentage negative pixels was calculated. RESULTS: Negative pixels were present in all 74 unenhanced adenomas with mean attenuation of 10 HU or less and in 14 of 16 unenhanced adenomas with mean attenuation above 10 HU. Of 184 enhanced adenomas, only 20 had mean attenuation of 10 HU or less, but 97 contained negative pixels (77 of these 97 masses had mean attenuation above 10 HU). Increase in percentage negative pixels was highly correlated with decrease in mean attenuation of both unenhanced and enhanced adenomas. None of the adrenal metastases had mean attenuation of 10 HU or less or contained negative pixels. CONCLUSION: The histogram method is far more sensitive than the 10-HU threshold method for diagnosis of adrenal adenomas at enhanced CT, with specificity maintained at 100%.     

Tumoren der Nebennieren

Clinical/methodical issue

Adrenal masses are very common and are usually detected incidentally. Less frequently, imaging is performed for the localization of the underlying lesion in the case of endocrine disease. The differentiation between adenomas and non-adenomas is fundamental.

Methodical innovations

Adenomas show a low density on unenhanced computed tomography (CT) and a rapid washout of contrast agents. In magnetic resonance imaging (MRI) adenomas are characterized by a low signal in opposed phase imaging as compared to in phase imaging.

Performance

According to the literature a density of less than 10 HU in an adrenal mass has a specificity of 98?% and a sensitivity of 71?% for the presence of an adenoma and MRI is slightly more sensitive. Some adrenal lesions, e.g. cysts or myelolipomas can be diagnosed with high accuracy due to pathognomonic findings.

Achievements

In the majority of cases the synopsis of imaging along with clinical and laboratory findings is necessary for a reliable diagnosis.

Practical recommendations

For the evaluation of an adrenal mass the CT examination should begin with an unenhanced scan, if necessary followed by a washout examination. In the case of MRI in phase and opposed phase imaging are essential components of the examination.     

Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma

OBJECTIVE: Attenuation values on CT of less than 10 H are considered characteristic of adrenal adenomas. Adrenal pheochromocytomas can infrequently contain fat that could result in low attenuation on CT. The purpose of our study was to determine if pheochromocytomas could be confused with adenomas by virtue of their attenuation values on unenhanced CT. MATERIALS AND METHODS: CT attenuation and size of nine adrenal nodules producing pheochromocytoma syndrome were measured on unenhanced CT in nine patients. For five patients who received IV contrast material, washout profiles were also calculated. RESULTS: Two of the nine patients had adrenal lesions with attenuation values of less than 10 H; one had a pheochromocytoma with an attentuation of 9.0 H, and the other had a medullary hyperplasia with an attenuation of 1.8 H. These two nodules showed evidence of microscopic fat at histologic examination. No macroscopic fat was seen on the CT scans. The remaining seven patients had lesions with attenuation values exceeding 10 H (mean value, 25.6 H; range, 1.8-41 H). Mean diameter of the nine tumors (including the hyperplastic nodule) was 3.2 cm (range, 0.8-6.7 cm; SD, +/- 2.3 cm). The two low-attenuation lesions also mimicked adenomas by displaying more than 60% contrast washout on 10-min-delayed contrast-enhanced scans, unlike the other three pheochromocytomas for which we had washout data. CONCLUSION: On CT, pheochromocytomas may have attenuation values less than 10 H and also may display more than 60% washout of contrast agents on delayed scanning. Adrenal pheochromocytomas should be included with adenomas in the differential diagnosis both for masses with low attenuation on unenhanced CT and for lesions exhibiting a high percentage of contrast washout.     

Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role?

PURPOSE: To evaluate chemical shift magnetic resonance (MR) imaging for the characterization of hyperattenuating adrenal masses. MATERIALS AND METHODS: Adrenal MR images obtained from January 1998 to February 2003 were reviewed. Patients were excluded if they did not undergo unenhanced computed tomography or did not have an adrenal mass with attenuation higher than 10 HU, adequate follow-up, or pathologic diagnosis for use as a reference standard. A diagnosis of adenoma required at least 24 weeks of stability on images. Thirty-eight masses in 36 patients were identified (27 adenomas, nine metastases, one adrenocortical oncocytoma, and one pheochromocytoma). Signal intensity (SI) decrease between in-phase and opposed-phase MR images was measured for the entire mass and normalized to the renal parenchymal SI. In 21 of 36 (58%) patients, dual-echo single-breath-hold MR imaging was used to eliminate misregistration. RESULTS: The attenuation of 61% (23 of 38) of all masses and 70% (19 of 27) of adenomas was 10-30 HU. With a threshold of 20% SI decrease, the sensitivity of chemical shift MR imaging for hyperattenuating adenoma was 67% (18 of 27 masses). When considering masses with attenuation of 10-30 HU, the sensitivity for adenoma was 89% (17 of 19 masses) and remained reasonable at 75% (six of eight masses) for adenomas with attenuation of 20-30 HU. Only one adenoma with attenuation higher than 30 HU had SI decrease of more than 20%. Specificity for diagnosis of adenoma was 100% (11 of 11). CONCLUSION: In certain circumstances, chemical shift MR imaging is a reasonable second imaging test for further characterization of a hyperattenuating adrenal mass.     

Incidental adrenal lesions detected on enhanced abdominal dual-energy CT: Can the diagnostic workup be shortened by the implementation of virtual unenhanced images?

Objective

To determine whether post-processing of the data from portal-phase enhanced dual-energy CT (DECT), with or without the addition of a late enhanced phase acquisition, may enable characterization of adrenal lesions without the need for acquisition of pre-contrast images.

Materials and methods

Twenty-two patients with 24 adrenal lesions underwent unenhanced, venous and delayed phase DECT. Of these lesions, 20 were found to be adrenal adenomas, on the basis of histopathology, unenhanced attenuation values between 0 and −10 HU, or stability over at least 6 months.For all 24 lesions, true and virtual unenhanced attenuation values were measured based on the data of the portal (VNCp) and the delayed (VNCd) DECT acquisition. The absolute washout values based on the true non-contrast (TNC) and the VNCp and VNCd image series were also measured. The washout was also calculated based on the iodine concentration measured from both contrast-enhanced acquisitions.

Results

Mean virtual unenhanced attenuation values of all lesions calculated from the portal phase images was 12.6 HU, and was 4.02 HU higher than the values based on true unenhanced images (p = 0.020). Washout values calculated from virtual unenhanced attenuation based on the VNCp were also significantly different (p = 0.0304) while those calculated from VNCd and from iodine concentration correlated with the corresponding values based on the true unenhanced values (p > 0.999).

Conclusions

Our data indicate that attenuation values of adrenal adenomas based on virtual unenhanced images are significantly higher than those obtained with true unenhanced images. An incidental adrenal lesion with a virtual unenhanced attenuation lower than 10 HU can thus be safely characterized as an adenoma.     

Differentiation of Adrenal Adenoma and Nonadenoma in Unenhanced CT: New Optimal Threshold Value and the Usefulness of Size Criteria for Differentiation

Objective

To determine the optimal threshold for the attenuation values in unenhanced computed tomography (CT) and assess the value of the size criteria for differentiating between an adrenal adenoma and a nonadenoma.

Materials and Methods

The unenhanced CT images of 45 patients at our institution, who underwent a surgical resection of an adrenal masses between January 2001 and July 2005, were retrospectively reviewed. Forty-five adrenal masses included 25 cortical adenomas, 12 pheochromocytomas, three lymphomas, and five metastases confirmed by pathology were examined. The CT images were obtained at a slice thickness of 2 mm to 3 mm. The mAs were varied from 100 to 160 and 200 to 280, while the 120 KVp was maintained in all cases. The mean attenuation values of an adrenal adenoma and nonadenoma were compared using an unpaired t test. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy at thresholds of 10 HU, 20 HU, and 25 HU were compared. The diagnostic accuracy according to the size criteria from 2 cm to 6 cm was also compared.

Results

The twenty-five adenomas showed significantly lower (p < 0.05) attenuation values(mean ± SD; 16.3 ± 14.9) than the nonadenomas (38.1 ± 6.8). Nineteen (90%) of the 20 nonadenomas had attenuation values ranging from 30 to 50 HU. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for diagnosing adenomas were 36%, 100%, 100%, 56%, and 64%, respectively, at a threshold of 10 HU; 60%, 100%, 100%, 67%, and 78%, respectively, at a threshold of 20 HU; and 72%, 95%, 95%, 73%, and 82%, respectively, at a threshold of 25 HU. The adenomas had a significantly (p < 0.05) smaller diameter (2.44 ± 1.24 cm) than the nonadenomas (5.09 ± 2.37 cm). The size criteria using a diameter of 4-6 cm showed a sensitivity > 90% but a specificity < 70%. Size criteria of 2 or 3 cm had a high specificity of 100% and 80% but a low sensitivity of 20% and 60%.

Conclusion

The threshold attenuation values of 20 or 25 HU in the unenhanced CT appear optimal for discriminating an adrenal adenoma from a nonadenoma. The size criteria are of little value in differentiating adrenal masses because of their low specificity or low sensitivity.     

Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses

PURPOSE: To retrospectively compare the accuracy of delayed enhanced computed tomography (CT) and chemical shift magnetic resonance (MR) imaging for characterizing hyperattenuating adrenal masses at CT, with either follow-up imaging or pathologic review as the reference standard. MATERIALS AND METHODS: The institutional review board approved this retrospective study with a waiver of patient informed consent. Forty-three hyperattenuating adrenal masses (>10 HU) on unenhanced CT images were found in 34 patients (23 men and 11 women; mean age, 52.7 years) by reviewing radiologic reports. These lesions were retrospectively analyzed with delayed enhanced CT and chemical shift MR. The diagnostic accuracy of CT by using absolute percentage loss of enhancement (PLE) and relative PLE and of chemical shift MR by using adrenal-to-spleen ratio (ASR) or signal intensity index (SII) were obtained to determine which modality was more accurate for lipid-poor adenoma. For CT, an adenoma was diagnosed if a mass had an absolute PLE greater than 60% and a relative PLE greater than 40%. For MR, an adenoma was diagnosed if a mass had an ASR of 0.71 or an SII greater than 16.5%. McNemar test was used to compare diagnostic performance of CT and MR. RESULTS: Hyperattenuating adrenal masses included 37 adenomas and six nonadenomas. The sensitivity, specificity, and accuracy for adenoma at CT were 97% (36 of 37), 100% (six of six), and 98% (42 of 43), respectively, and at MR were 86% (32 of 37), 50% (three of six), and 49% (21 of 43), respectively. CT helped confirm five more adenomas and three more metastatic tumors than did MR. However, there was no significant difference for diagnostic accuracy between these two imaging modalities (P>.05) CONCLUSION: Delayed enhanced CT can characterize additional hyperattenuating adrenal masses that cannot be characterized with chemical shift MR.     

18F-FDG PET/CT in the evaluation of adrenal masses.

Our purpose was to evaluate the performance of (18)F-FDG PET/CT, using data from both the PET and the unenhanced CT portions of the study, in characterizing adrenal masses in oncology patients. METHODS: One hundred seventy-five adrenal masses in 150 patients referred for (18)F-FDG PET/CT were assessed. Final diagnosis was based on histology (n = 6), imaging follow-up (n = 118) of 6-29 mo (mean, 14 mo), or morphologic imaging criteria (n = 51). Each adrenal mass was characterized by its size; its attenuation on CT, expressed by Hounsfield units (HU); and the intensity of (18)F-FDG uptake, expressed as standardized uptake value (SUV). Receiver operating characteristic curves were drawn to determine the optimal cutoff values of HU and SUV that would best discriminate between benign and malignant masses. RESULTS: When malignant lesions were compared with adenomas, PET data alone using an SUV cutoff of 3.1 yielded a sensitivity, specificity, positive predictive value, and negative predictive value of 98.5%, 92%, 89.3%, 98.9%, respectively. For combined PET/CT data, the sensitivity, specificity, positive predictive value, and negative predictive value were 100%, 98%, 97%, 100%, respectively. Specificity was significantly higher for PET/CT (P < 0.01). Fifty-one of the 175 masses were 1.5 cm or less in diameter. When a cutoff SUV of 3.1 was used for this group, (18)F-FDG PET/CT correctly classified all lesions. CONCLUSION: (18)F-FDG PET/CT improves the performance of (18)F-FDG PET alone in discriminating benign from malignant adrenal lesions in oncology patients.     

Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation

RATIONALE AND OBJECTIVES: We sought to assess the ability of (18)F-fluoro-2-deoxy-d-glucose (FDG) PET/CT to distinguish adrenal adenomas from nonadenomas in patients with suspected malignancy. METHODS: Fifty-nine adrenal masses were evaluated with coregistered (18)F-FDG PET (PET/CT). Two reviewers independently graded uptake of (18)F-FDG by visual inspection of the adrenal mass in comparison to liver and background. CT attenuation value of the adrenal mass and the standardized uptake value (SUV) of the mass, liver, background, and primary neoplasm (when visible) were measured. Mean SUVs of the adrenal mass, liver, and background and ratios of the SUVs were calculated. RESULTS: Of 47 adenomas, 43 measured <10 HU on unenhanced CT. Of 12, 12 nonadenomas measured >10 HU on unenhanced CT. Using qualitative assessment of FDG activity in the adrenal mass compared with liver, adenomas were less than, equal to, or more active than the liver in 51%, 38%, and 10%, respectively. Nonadenomas were less than, equal to, or more active than liver in 0%, 25%, and 75%, respectively. The mean SUV of adenomas (4.2) was significantly lower (P = .002) than that of their primary malignancies (9.2) but not that of liver (4.3). The mean SUV of adenomas was not significantly different than that of nonadenomas (5.2), but the mean adrenal/liver ratio (1.0) for the adenomas was significantly lower (P = .006) than that of the nonadenomas (2.1). CONCLUSION: Adrenal adenomas were better differentiated from nonadenomas using unenhanced CT measurements in combination with ratios of the SUVs. Adrenal mass activity, which was visibly less than liver, was more specific for adenoma, whereas adrenal mass activity visibly greater than liver was more specific for malignancy.     

Comparison of unenhanced CT and chemical shift MRI in evaluating lipid-rich adrenal adenomas

OBJECTIVE: Our aim was to evaluate adrenal adenomas in patients who underwent both unenhanced CT and chemical shift MRI to determine if adenomas can be characterized with MRI when the findings of CT are indeterminate. MATERIALS AND METHODS: Between January 1999 and June 2003, 40 patients (42 adrenal masses) underwent unenhanced CT and chemical shift MRI and were retrospectively analyzed. Hounsfield units, adrenal-to-spleen chemical shift ratio, and signal-intensity index were obtained for each adrenal mass. Qualitative analysis for loss of signal in each adrenal mass on the opposed-phase images was also performed by two reviewers and compared with the quantitative analyses. A lipid-rich adenoma was diagnosed if the mass measured equal to or less than 10 H, had an adrenal-to-spleen chemical shift ratio of less than 0.71, and had a signal-intensity index of greater than 16.5% or if the mass fulfilled two of the preceding criteria and had follow-up imaging without change. RESULTS: The sensitivities and specificities for diagnosing a lipid-rich adenoma using the qualitative, adrenal-to-spleen chemical shift ratio, signal-intensity index, and unenhanced CT attenuation analyses were 92% (33/36) and 17% (1/6), 100% (36/36) and 100% (6/6), 100% (36/36) and 67% (4/6), and 78% (28/36) and 83% (5/6), respectively. Twenty-eight (67%) lipid-rich adenomas measured equal to or less than 10 H, had an adrenal-to-spleen chemical shift ratio of less than 0.71, and had a signal-intensity index of greater than 16.5%. Eight masses (19%) measured greater than 10 H but had an adrenal-to-spleen chemical shift ratio of less than 0.71 and a signal-intensity index greater than 16.5% and were unchanged at follow-up. CONCLUSION: Eight (62%) of 13 adrenal adenomas measuring greater than 10 H on unenhanced CT were definitively characterized with chemical shift MRI.     

Differentiation of adrenal tumors in patients with hepatocellular carcinoma: Adrenal adenoma versus metastasis

Objective

To investigate whether computed tomography (CT) attenuation test for differential diagnosis of adrenal nodule is applicable in patients with hepatocellular carcinoma (HCC) which shows similar image characteristics to adrenal adenoma.

Materials and methods

This retrospective study was approved by our institutional review board, and the requirement for informed consent from study patients was waived. Searching picture archiving and communication system, we identified 3678 patients with HCC who underwent upper abdominal unenhanced CT scans between April 2002 and March 2010, and 114 adrenal nodules (39 adenomas and 75 metastases) were included for analysis. Ten nodules were confirmed pathologically while 104 had imaging diagnosis (enlarged or emerged during the study period). Size, CT number, and the internal characteristics of the lesions were recorded.

Results

Mean CT numbers of adrenal adenomas were significantly lower than those of metastases (P < 0.0001, t-test) on unenhanced CT. Thresholds of 17 and 33 Hounsfield units (HU) provided the following sensitivity, specificity, and accuracy: 46.2%, 100%, and 81.6% at 17 HU, and 94.9%, 89.3%, and 91.2% at 33 HU, respectively. The area under receiver operating characteristic curve for the CT number test was 0.96. Metastases were significantly larger than adrenal adenoma (P = 0.009, t-test). However, the accuracy of testing using mass size was 64.0% at most. All adenomas and metastases were depicted as homogeneous masses with the exception of two metastases that presented as heterogeneous masses (necrotic or lipomatous).

Conclusion

Adrenal adenomas can be differentiated from HCC metastases using CT number on unenhanced CT.     

Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay

PURPOSE: To retrospectively evaluate the accuracy of precontrast attenuation, relative percentage washout (RPW), and absolute percentage washout (APW) in distinguishing benign from malignant adrenal masses at multi-detector row computed tomography (CT). MATERIALS AND METHODS: This HIPAA-compliant retrospective study had institutional review board approval; the need for informed consent was waived. One hundred twenty-two adrenal masses were evaluated in 99 patients (51 men, 48 women; age range, 37-86 years) who had undergone CT performed according to the study protocol and who either were given a pathologic diagnosis or underwent follow-up imaging. Unenhanced images were obtained before administration of 120 mL of an intravenous contrast agent with a 75-second scan delay. Delayed images were obtained after 10 minutes. RPW and APW were computed. Receiver operating characteristic (ROC) analysis was performed to compare mean attenuation and both RPW and APW. Analysis was first performed with the exclusion of pheochromocytomas, myelolipomas, and cysts. Precontrast attenuation criteria specific for benignity or malignancy were determined, and ROC analysis of results for the entire nonpheochromocytoma group was then performed. RESULTS: By using an RPW of 37.5% and excluding cysts and myelolipomas, all malignant lesions were detected with a sensitivity of 100% (17 of 17 lesions) and a specificity of 95% (90 of 95 lesions). Area under the binomial ROC curve (A(z)) values were 0.912, 0.985, and 0.892 for precontrast attenuation, RPW, and APW, respectively. Precontrast attenuation of less than 0 or more than 43 HU indicated benign and malignant entities, respectively. Incorporation of these criteria into the APW analysis yielded a sensitivity of 100% (17 of 17 lesions) and a specificity of 98% (93 of 95 lesions) for a threshold washout value of 52.0%. This attenuation-corrected APW generated the greatest A(z) value (ie, 0.988). Combining all the information available from the protocol yielded a sensitivity of 100% (17 of 17 lesions) and a specificity of 98% (98 of 100 lesions) for differentiating benign from malignant masses. CONCLUSION: Precontrast attenuation of less than 0 HU supercedes the washout profile in the evaluation of an individual adrenal mass. Noncalcified, nonhemorrhagic adrenal lesions with precontrast attenuation of more than 43 HU should be considered suspicious for malignancy.     

Adrenal masses falsely diagnosed as adenomas on unenhanced and delayed contrast-enhanced computed tomography: Pathological correlation

Objectives To assess the accuracy of CT for the diagnosis of histologically confirmed adrenal adenoma and nonadenoma using CT numbers. Materials and methods Our study included 91 adrenal masses in 83 patients; histopathological diagnoses were 45 adenomas, 31 pheochromocytomas, 6 hyperplasias, 4 metastasis, and 5 miscellaneous lesions. Unenhanced CT in 46 patients and unenhanced and delayed contrast-enhanced (DCE) CT in 37 patients were retrospectively reviewed to examine the correlation between CT findings and those on pathological examination and to obtain diagnostic accuracy. Results Sensitivity, specificity, and accuracy for adenoma were 40% (18/45), 91% (42/46), and 66% (60/91) with unenhanced CT, and 96% (24/25), 61% (11/18), and 81% (35/43) with DCE CT. Adrenal masses falsely diagnosed as adenoma on unenhanced CT included three hyperplasias and one endothelial cyst, and those falsely diagnosed as adenoma on DCE CT were five pheochromocytomas, one oncocytic coritical tumor, and one primary pigmented nodular adrenocortical dysplasia. Twenty-five lipid-poor adenomas were falsely diagnosed as nonadenomas on unenhanced CT and one degenerated adenoma both on unenhanced CT and on DCE CT. Conclusion Diagnosing adenoma merely on CT numbers can lead to misdiagnosis. The lower specificity than expected is due to pheochromocytomas presenting as false positives. An erratum to this article can be found at     

Delayed enhanced CT of lipid-poor adrenal adenomas

OBJECTIVE. Although representing a minority of adrenal adenomas, the lipid-poor variety cannot be accurately identified on unenhanced CT or chemical shift MR imaging. We compared the delayed contrast-enhanced CT features of lipid-poor adenomas with those of lipid-rich adenomas and of adrenal nonadenomas to determine whether there were differences in the washout features between these groups of lesions. SUBJECTS AND METHODS. Eighteen proven lipid-poor adenomas, 56 lipid-rich adenomas, and 40 adrenal nonadenomas underwent CT before, immediately after, and 15 min delay after IV contrast injection. Region-of-interest measurements were made of all adrenal lesions at the three time points. The degree of enhancement, enhancement washout, percentage enhancement washout, and relative percentage enhancement washout were calculated for each adrenal mass. Pooled data were analyzed statistically. Optimal threshold values for diagnosing adrenal adenomas were also determined. RESULTS. The mean CT attenuation of lipid-poor adenomas was significantly higher than that of lipid-rich adenomas at all three phases but not significantly different from that of nonadenomas. The mean percentage enhancement washout on images obtained 15 min after administration of contrast material was similar for lipid-rich and lipid-poor adenomas but was significantly higher than that of nonadenomas. The mean relative percentage enhancement washout was significantly different among all three groups. CONCLUSION. Lipid-poor adenomas cannot be differentiated from adrenal nonadenomas on the basis of a single mean attenuation value. However, lipid-poor adrenal adenomas show enhancement and enhancement washout features nearly identical to lipid-rich adenomas and can be distinguished from nonadenomas on the basis of a percentage washout threshold value of 60% and a relative percentage washout of 40%.     

Radiologie der Nebennieren

An important principle of diagnostic imaging of the adrenal glands is to characterize an adrenal mass as an adenoma using computed tomography (CT) or magnetic resonance imaging (MRI) techniques. Most techniques exploit the fact that typical adrenal adenomas are lipid-rich so that lipid-poor adenomas, however, remain a diagnostic problem. A CT attenuation ≤?10 HU, more than 10% negative pixels as demonstrated by histogram analysis, an absolute washout of more than 60%, a relative washout of more than 40% and a signal drop of more than 20% in opposed-phase images are characteristic for adrenal adenomas. Endocrine dysfunction is diagnosed biochemically and not by means of imaging but are necessary to localize a functioning tumor. An important principle is to combine anatomical with functional imaging studies. Percutaneous biopsy of adrenal glands is only indicated when an adrenal mass is the only potential metastasis of a diagnosed primary tumor.     

Adrenal neoplasms

Adenoma, myelolipoma, phaeochromocytoma, metastases, adrenocortical carcinoma, neuroblastoma, and lymphoma account for the majority of adrenal neoplasms that are encountered in clinical practice. A variety of imaging methods are available for evaluating adrenal lesions including ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and nuclear medicine techniques such as meta-iodobenzylguanidine (MIBG) scintigraphy and positron-emission tomography (PET). Lipid-sensitive imaging techniques such as unenhanced CT and chemical shift MRI enable detection and characterization of lipid-rich adenomas based on an unenhanced CT attenuation of ≤10?HU and signal loss on opposed-phase compared to in-phase T1-weighted images, respectively. In indeterminate cases, an adrenal CT washout study may differentiate adenomas (both lipid-rich and lipid-poor) from other adrenal neoplasms based on an absolute percentage washout of >60% and/or a relative percentage washout of >40%. This is based on the principle that adenomas show rapid contrast washout while most other adrenal neoplasms including malignant tumours show slow contrast washout instead. (18)F-2-fluoro-2-deoxy-d-glucose-PET ((18)FDG-PET) imaging may differentiate benign from malignant adrenal neoplasms by demonstrating high tracer uptake in malignant neoplasms based on the increased glucose utilization and metabolic activity found in most of these malignancies. In this review, the multi-modality imaging appearances of adrenal neoplasms are discussed and illustrated. Key imaging findings that facilitate lesion characterization and differentiation are emphasized. Awareness of these imaging findings is essential for improving diagnostic confidence and for reducing misinterpretation errors.     

The value of 15-minute delayed contrast-enhanced CT to differentiate hyperattenuating adrenal masses compared with chemical shift MR imaging

Objectives

To investigate the diagnostic performance of 15-min delayed contrast-enhanced computed tomography (15-DECT) compared with that of chemical shift magnetic resonance (CSMR) imaging in differentiating hyperattenuating adrenal masses and to perform subgroup analysis in underlying malignancy and non-malignancy.

Methods

This study included 478 adrenal masses in 453 patients examined with 15-DECT and 235 masses in 217 patients examined with CSMR. Relative percentage washout (RPW) and absolute percentage washout (APW) on 15-DECT, and signal intensity index (SII) and adrenal-to-spleen ratio (ASR) on CSMR were measured. Sensitivity, specificity and accuracy of 15-DECT and CSMR were analysed for characterisation of adrenal adenoma. Subgroup analyses were performed in patients with and without underlying malignancy. Attenuation and size of the masses on unenhanced CT correlated with the risk of non-adenoma.

Results

RPW calculated from 15-DECT showed the highest diagnostic performance for characterising hyperattenuating adrenal masses regardless of underlying malignancy, and the sensitivity, specificity and accuracy were 91.7 %, 74.8 % and 88.1 %, respectively in all patients. The risk of non-adenoma increased approximately threefold as mass size increased 1 cm or as its attenuation value increased by 10 Hounsfield units.

Conclusions

15-DECT was more accurate than CSMR in characterising hyperattenuating adrenal masses regardless of underlying malignancy.

Key Points

? Delayed contrast-enhanced CT and chemical shift magnetic resonance (CSMR) characterise adrenal lesions. ? 15-min DECT is more accurate than CSMR in characterising hyperattenuating adrenal masses. ? Sensitivity of CSMR decreases as the CT attenuation of adenomas increases. ? Risk of non-adenoma is increased 2.9-fold as size increased by 1 cm. ? Risk of non-adenoma is increased 2.9-fold as attenuation increased by 10 HU.     

State-of-the-art adrenal imaging.

The adrenal gland is a common site of disease, and detection of adrenal masses has increased with the expanding use of cross-sectional imaging. Radiology is playing a critical role in not only the detection of adrenal abnormalities but in characterizing them as benign or malignant. The purpose of the article is to illustrate and describe the appropriate radiologic work-up for diseases affecting the adrenal gland. The work-up of a suspected hyperfunctioning adrenal mass (pheochromocytoma and aldosteronoma) should start with appropriate biochemical screening tests followed by thin-collimation computed tomography (CT). If results of CT are not diagnostic, magnetic resonance (MR) and nuclear medicine imaging examinations should be performed. CT has become the study of choice to differentiate a benign adenoma from a metastasis in the oncology patient. If the attenuation of the adrenal gland is over 10 HU at nonenhanced CT, contrast material-enhanced CT should be performed and washout calculated. Over 50% washout of contrast material on a 10-minute delayed CT scan is diagnostic of an adenoma. For adrenal lesions that are indeterminate at CT in the oncology patient, chemical shift MR imaging or adrenal biopsy should be performed. Certain features can be used by the radiologist to establish a definitive diagnosis for most adrenal masses (including carcinoma, infections, and hemorrhage) based on imaging findings alone.